GlassScriptPhysician profile
Jason Thompson
NPI 1740236694
$247,677.40
in general payments reported to CMS, 2019-2025
25 companies · $71K in 2025
The $71K reported for 2025 was more than what 99% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,097 · 2020: $6,448 · 2021: $45K · 2022: $63K · 2023: $36K · 2024: $16K · 2025: $71K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $116K · Travel and Lodging: $5,156 · Food and Beverage: $2,851.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $115,871.31 |
| Travel and Lodging | $5,156.03 |
| Food and Beverage | $2,851.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $229,146.51 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Esperion Therapeutics, INC. | $7,515.10 | 2021 | |
| Medtronic, INC. | $7,044.65 | 2021-2025 | Venaseal |
| Medtronic Vascular, INC. | $1,200.00 | 2020 | |
| Novartis Pharmaceuticals Corporation | $542.18 | 2021-2025 | |
| Abbott Laboratories | $359.71 | 2019-2025 | Cardiomems |
| Boehringer Ingelheim Pharmaceuticals, INC. | $316.32 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $261.12 | 2019-2023 | Xarelto |
| Pfizer INC. | $184.78 | 2021-2025 | |
| Amgen INC. | $154.68 | 2019-2025 | Repatha, Repatha |
| Sanofi-Aventis U.S. LLC | $153.89 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $144.52 | 2022-2025 | Eliquis, Camzyos |
| Merck Sharp & Dohme LLC | $138.92 | 2021-2023 | Verquvo |
| Organogenesis INC. | $117.51 | 2022 | |
| Abiomed | $95.21 | 2022-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $58.02 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $41.78 | 2022-2023 | Brilinta |
| Actelion Pharmaceuticals US, INC. | $39.61 | 2022-2024 | Uptravi, Opsumit |
| Lantheus Medical Imaging, INC. | $35.33 | 2022 | |
| Biocompatibles, INC. | $30.45 | 2019 | |
| Atricure, INC. | $29.24 | 2023 | |
| Astellas Pharma US INC | $23.21 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $17.29 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.09 | 2025 | |
| Z-Medica, LLC | $12.28 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.